In a new study, researchers investigated whether weekly and monthly subcutaneous buprenorphine depot formulations were noninferior to a daily sublingual combination of buprenorphine and naloxone for the...
The FDA’s Psychopharmacologic Drugs Advisory Committee recently reviewed and voted on whether to recommend lofexidine, a non-opioid drug, for the management of opioid withdrawal.
In a recent study, researchers investigated whether cannabis use influenced the relationship between pain and negative mood symptoms, such as depression, and whether self-efficacy influenced these...
Opioid and substance use disorders have reached epidemic levels in the United States. In a recent study, researchers explored the prevalence of visits due to opioid-related complications in US emergency...
In a recent study, researchers compared extended-release naltrexone hydrochloride with daily buprenorphine hydrochloride with naloxone hydrochloride for promoting abstinence from heroin or opioids among...
Primary care is often underutilized in the treatment of opioid and alcohol use disorders. In a recent study, researchers sought to determine whether collaborative care could help to improve outcomes among...
In a recent study, researchers analyzed rates of opioid-related overdose admissions to the ICU and in-hospital deaths, and their effects on ICU resources.
In a recent study, researchers sought to determine potential reasons why physicians do not prescribe a certain pharmacotherapy to capacity for opioid addiction, or do not prescribe it at all. Findings were...
A recent study compared the effects of extend-release tramadol with clonidine and buprenorphine on withdrawal symptoms and retention among patients with opioid use disorder.
